Work

To042antiproteinuric Effect of Sparsentan, a Dual Angiotensin Ii and Endothelin Type a Receptor Antagonist, in Patients With Primary Focal Segmental Glomerulosclerosis (fsgs): a Subgroup Analysis of the Duet Trial